Please ensure Javascript is enabled for purposes of website accessibility

Why Arrowhead Pharmaceuticals Stock Jumped Today

By Prosper Junior Bakiny – Updated Oct 15, 2020 at 5:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Vertex's losses are Arrowhead's gains.

What happened?

Shares of Arrowhead Pharmaceuticals (ARWR 3.47%) rose sharply on Thursday and closed today's trading session up 9.9% after climbing by as much as 14.4%. The drugmaker did not report any news, but biotech giant Vertex Pharmaceuticals (VRTX 0.37%) released an update regarding one of its pipeline candidates, and the update bodes well for Arrowhead and its shareholders. 

So what

On Wednesday evening, Vertex announced it would discontinue the development of VX-814, a potential treatment for alpha-1 antitrypsin deficiency (AATD), a genetic condition that can cause lung or liver disease. The company decided to do so because VX-814 seems to have caused elevated liver enzymes in several patients during a phase 2 clinical trial. The news sent Vertex's stock plunging. Meanwhile, Arrowhead is also targeting AATD. The company is developing ARO-AAT as a treatment for liver disease associated with the illness.

Arrows pointing straight up on a blackboard.

Image source: Getty Images.

Last month, Arrowhead reported positive interim results from a phase 2 study for ARO-AAT. During the trial, the experimental medicine caused an improvement in liver stiffness and a decrease in liver injury in AATD patients. Given that there are few therapy options for AATD, it isn't surprising to see investors bidding up shares of Arrowhead after Vertex announced that it would halt the development of VX-814.

Now what

Arrowhead's potential AATD medicine does seem promising, but it might be worth it for investors to temper their expectations. While Vertex's VX-814 flopped, the biotech is developing VX-864, another experimental treatment for AATD. Vertex expects to release data from a phase 2 clinical trial for VX-864 during the first half of 2021. At any rate, both healthcare companies still have a long way to go before they can hope to launch their respective AATD medicines on the market.

Prosper Junior Bakiny owns shares of Vertex Pharmaceuticals. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arrowhead Pharmaceuticals, Inc. Stock Quote
Arrowhead Pharmaceuticals, Inc.
$34.91 (3.47%) $1.17
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$298.53 (0.37%) $1.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.